The pharmaceutical lab Biolab acquired the Brazilian operation of Actavis, a company of the Israeli group Teva that acts mainly in the production of medicines with action in the nervous system. The transaction amount has not been disclosed.

“The discussions with Teva started in January as the group is making adjustments to its global operation,” said Cleiton de Castro Marques, purchaser CEO.

With the acquisition, Biolab seeks to grow in the segment of antidepressants. Today, half of the company’s revenue comes from the cardiology area.

The column ascertained that Actavis has invoiced around BRL 34 million in the country in the 12 months accumulated up to March.

The company has 150 employees, a plant in Rio and 30 generic products in its portfolio. Biolab’s revenue in 2017 was BRL 1.3 billion and it has 2,500 employees under its brand.
Learn more
arrow_backward See more articles
Customer Service 0800 724 6522
Be connected
Nós usamos cookies e outras tecnologias semelhantes para melhorar a sua experiência, personalizar publicidade e recomendar conteúdo de seu interesse. Ao navegar em nosso site, você está ciente de tal monitoramento. Para mais informações, consulte a nossa nova Política de Privacidade.